An Open Labeled RCT on the Effect of Additional hCG Injection for LPS on Pregnancy Outcomes in IHH Patients
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Luteal phase deficiency (LPD) accounts for most failures of assistant artificial reproduction
(ART) and early pregnancy loss for patients with idiopathic hypogonadotropic hypogonadism
(IHH). Luteal phase support (LPS) is one of the indispensable interventions in ART treatments
for IHH patients, which includes progestin, estrogen, human chorionic gonadotropin (hCG), and
GnRH agonists (GnRHa). We aim to verify additional hCG injection 48 hours following routine
hCG trigger and ovulation for LPS on the basis of supplementation of estrogen and
dydrogesterone could improve clinical pregnancy rate, cumulative pregnancy rate, live birth
rate and the prevalence of early pregnancy loss and ovarian hyperstimulation syndrome (OHSS)
by an open labeled, prospective, and randomized clinical trial (RCT) in IHH patients in a
single center.